Skip to main content
LQDA logo

Liquidia Corporation (LQDA) Stock: Price, Forecast & Analyst Target

Liquidia Corporation (LQDA) — MoonshotScore 36/100 (Weak band), calculated Nov 18, 2026. Price $56.63 (+0.41%), as of the Nov 19, 2026 trading session; market cap $5.10B. Expected results Mar 4, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$56.63 +$0.23 (+0.41%) Market Cap $5.10B

Liquidia Corporation · LQDA · NASDAQ · Healthcare · Medical - Pharmaceuticals

Research dated 2026-09-13: Liquidia is a biopharmaceutical company that sells pulmonary arterial hypertension therapies. The central question: can the company sustain the inflection from losses to profitability and continue expanding without exhausting its cash cushion? After years of setbacks, the company just posted profits in consecutive quarters, driven by uptake of YUTREPIA, an inhaled formulation of treprostinil. The rate of growth and the management's commitment to spending more on research while maintaining margin expansion will determine whether the current trajectory holds.

Price as of Nov 19, 2026

Key Statistics

36 of 100

MoonshotScore v2 · Liquidia (LQDA)

Weak
Business Quality Solid (64)
Financial Safety Strained (36)
Valuation Full (55)
Growth Durability Compounding (81)
Momentum Rising (76)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 0 of the last 3 reports
  • Altman Z 3.31 · Piotroski F 4

Helping: durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LQDA (57 recorded, newest six shown)
RecordedScoreBand
36Weak
36Weak
36Weak
36Weak
36Weak
36Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$56.63
Change on the day+0.41%
52-week range$22.31–$93.61
Market capitalisation$5.10B—
Price / earnings (trailing)30.51
Shares traded on the day1.32M
Beta (volatility vs the S&P 500)0.54

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $22, high $90, latest $57. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $90 $22 high $90 Mar 5, 2026 · Earnings results · reported above the recorded estimate · close $361May 11, 2026 · Earnings results · reported above the recorded estimate · close $422Aug 12, 2026 · Earnings results · reported above the recorded estimate · close $743Nov 10, 2026 · Earnings results · reported below the recorded estimate · close $574 Oct 17, 2025 Nov 19, 2026 · $57 $22Oct 17, 2025$24Oct 31, 2025$28Nov 14, 2025$33Nov 28, 2025$33Dec 12, 2025$34Dec 26, 2025$36Jan 9, 2026$41Jan 23, 2026$43Feb 6, 2026$34Feb 20, 2026$36Mar 6, 2026$36Mar 20, 2026$38Apr 2, 2026$39Apr 17, 2026$38May 1, 2026$57May 15, 2026$62May 29, 2026$71Jun 12, 2026$78Jun 26, 2026$78Jul 10, 2026$86Jul 24, 2026$90Aug 7, 2026$69Aug 21, 2026$69Sep 4, 2026$67Sep 18, 2026$29Oct 2, 2026$34Oct 16, 2026$45Oct 30, 2026$57Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Liquidia (LQDA): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Liquidia (LQDA), and what does it report?

Short answer · as of

Liquidia manufactures inhaled treprostinil (YUTREPIA) and distributes a generic injectable version of the same molecule.

The inhaled form is the innovation: it changes the route of administration from injection to inhalation, which alters dosing burden and patient tolerability in pulmonary arterial hypertension, a rare lung disease characterized by elevated pressure in pulmonary arteries. The company also earns revenue from services, but products dominate the mix.

Reported numbers measure net product and service revenue against operating costs and R&D spending. The critical reading is that this is not a pure-play development company anymore. Results show a commercial-stage enterprise whose inhaled treprostinil formulation is generating significant adoption, and management is deliberately scaling research to develop additional inhaled treprostinil products rather than expanding into unrelated molecules.

2 · Latest results

What do the latest results show for Liquidia (LQDA)?

Revenue accelerated sharply over recent periods, with each period showing growth over the prior year. The magnitude of that acceleration widened. Profitability swung from significant losses through prior calendar periods to a series of positive net results in the current fiscal year. The swing reflects both the revenue uptick and the operating leverage embedded in the cost structure: gross margins are elevated, and SG&A has not grown in proportion to revenue gains. Management commentary signals intent to increase R&D spending in the second half of the current year relative to the first half, and again in the following calendar year. The stated expectation is that revenue will continue to expand while profitability grows in absolute terms—a claim that hinges on the continued adoption rate of the inhaled formulation and the company's ability to manage the new research investments without creating a cost structure that revenue cannot support.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$225.30M Nov 10, 2026
Latest report · revenue estimate
$214.18M Nov 10, 2026
Latest report · revenue vs estimate
Above estimate Nov 10, 2026
Latest report · EPS vs estimate
Below estimate Nov 10, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 10, 2026$225.30M$214.18M−$2.6400$0.9600
Aug 12, 2026$171.68M$168.48M$0.7400$0.7000
May 11, 2026$132.87M$119.44M$0.5200$0.3400
Mar 5, 2026$92.02M$88.59M$0.1500$0.0800
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$54M-$4M-$0.04 (diluted)
Q4 FY2025$92M$15M$0.15 (diluted)
Q1 FY2026$133M$53M$0.52 (diluted)
Q2 FY2026$172M$75M$0.74 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Liquidia (LQDA)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The balance sheet shows abundant cash relative to debt, and the gap widened in recent quarters. The company holds no long-term investments and minimal capital spending. Cash generation from operations turned sharply positive in the most recent quarter after declining in intermediate quarters, which suggests the shift to profitability is material and not a one-off timing effect.

Management commentary and the quality screening metrics indicate the company is not in financial distress. The runway calculation derived from current cash and annualized cash use spans multiple years, providing buffer for increased R&D and any disruption in revenue growth. The specific risk is not solvency but rather whether the inherent profit margin of treprostinil products—now that they have reached meaningful volume—can support both higher R&D and investor expectations for sustained growth.

4 · What to check next?

What should you watch next at Liquidia (LQDA)?

Short answer · as of

The next earnings report is expected on Mar 4, 2027.

Analyst revenue estimates for the next several years assume accelerating topline results, driven by continued adoption of the inhaled formulation. The estimates imply margin expansion, meaning revenue growth is expected to exceed cost growth. The next reported earnings will provide the first test of whether the company's guidance on R&D investment is consistent with those estimates.

Insider transactions over the recent period show selling concentrated among officers, with no recorded purchases. The pattern suggests either tax-motivated withholding on vesting compensation or a signal of confidence in the current valuation; Form filings do not distinguish between them. Monitor the earnings call and any announcements about clinical development in the near term, as those will signal whether management is executing on the R&D scaling it has announced.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Liquidia compare with its peers?

Short answer

Liquidia's score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Pulmonary arterial hypertension therapies fall into several categories: intravenous, subcutaneous, inhaled, and oral formulations of various compounds. Liquidia's inhaled treprostinil occupies a distinct position because inhalation is a non-invasive delivery route for a molecule that has existing data in other forms. The commercial advantage is reduced treatment burden compared to injected routes.

Liquidia differs from other treprostinil producers and PAH therapy makers in that it owns both the advanced formulation (inhaled) and the commodity form (generic injectable). That vertical integration—owning both premium and generic lines—provides revenue diversification and supply chain control. The trade-off is that it exposes the company to margin compression if generic pricing becomes competitive pressure, though the injectable is not the growth driver in current results.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BeOne Medicines Ltd. (ONC) Same industry, near in market value$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
Cullinan Therapeutics, Inc. (CGEM) Same industry, near in market value$9.07 Nov 19, 2026$589M51 5-pillar Nov 18, 2026
Cogent Biosciences, Inc. (COGT) Named competitor$27.74 Nov 19, 2026$4.83B50 5-pillar Nov 18, 2026
Galecto, Inc. (DMRA) Same industry, near in market value$24.30 Nov 19, 2026$1.50B50 5-pillar Nov 18, 2026
111, Inc. (YI) Same industry, near in market value$2.51 Nov 19, 2026$22.1M40 5-pillar Nov 18, 2026
Liquidia (LQDA) — this page$56.63$5.10B36
High Tide Inc. (HITI) Same industry, near in market value$2.29 Nov 19, 2026$204M36 5-pillar Nov 18, 2026
Satellos Bioscience Inc. Common Stock (MSLE) Same industry, near in market value$5.80 Nov 19, 2026$123M32 5-pillar Nov 18, 2026
Kyntra Bio, Inc. (KYNB) Same industry, near in market value$1.83 Nov 19, 2026$7.41M32 5-pillar Nov 18, 2026
Rein Therapeutics, Inc. (RNTX) Same industry, near in market value$0.37 Nov 19, 2026$31.7M30 5-pillar Nov 18, 2026
PetMed Express, Inc. (PETS) Same industry, near in market value$0.90 Nov 18, 2026$20.0M29 5-pillar Nov 18, 2026
LifeMD, Inc. (LFMDP) Same industry, near in market value$18.75 Nov 19, 2026$133M22 5-pillar Nov 18, 2026
Pomdoctor Limited (POM) Same industry, near in market value$1.61 Nov 19, 2026$57.9M21 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$54.00 – $130.00
Consensus target
$78.18
Median target
$65.00

Consensus record · Captured .

Measured against a quoted price of $56.63 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 26, 2026

Transactions
181
Identified insiders
17
Purchases
0
Sales
89
Other transactions
92

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LQDA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LQDA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Liquidia (LQDA)?

Read these with our analysis →

LQDA Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

What does YUTREPIA do that other treprostinil products do not?

YUTREPIA is an inhaled dry-powder formulation of treprostinil, which means it reaches the lungs directly without requiring intravenous or subcutaneous injection. This avoids the need for central lines or needle insertion and offers dosing flexibility for pulmonary arterial hypertension patients. The molecule itself—treprostinil—is an established prostacyclin analogue; the innovation is in the delivery mechanism.

Can the company fund the R&D increase it has announced without depleting cash?

Current cash and the trajectory of operating cash flow—positive in the most recent quarter—suggest the company has sufficient liquidity to fund that investment while continuing to grow absolute profitability. The risk is not bankruptcy but rather whether the revenue growth assumption underlying analyst estimates holds.

Why are insiders selling if the business is performing this well?

Insider filings show net selling concentrated over a narrow window, with transactions classed as equity compensation withholding (M-Exempt category) dominant in the total. Withholding on vesting shares is tax-driven and does not necessarily signal a view on the company's prospects. However, the absence of any insider purchases over the recent period is notable and warrants attention to the earnings call commentary and any clinical or competitive announcements that might explain executive caution.

What is the breakeven point for cash generation, and when might the company reach it permanently?

The company currently burns cash through operating and capital spending at an annualized rate that is well below the operating profit it posted in the most recent quarter. This suggests operating profitability is now structural, not cyclical. The critical threshold is whether gross margin on inhaled treprostinil remains stable as volume increases, and whether SG&A growth remains proportional to revenue. If both hold, the company could approach cash-positive operations within quarters. Analyst guidance and the next earnings call will clarify the timing.

What is the LQDA stock price today?

The last price recorded for Liquidia Corporation (LQDA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LQDA price target?

The analyst consensus price target for Liquidia Corporation (LQDA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 1. What is Liquidia (LQDA), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Liquidia (LQDA)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for Liquidia (LQDA)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Cash runway cross-check (ours); Distress and quality screens
  • 4. What should you watch next at Liquidia (LQDA)?: Analyst revenue and earnings estimates (average); Insider transactions, last 180 days; Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 5. How does Liquidia compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands)
  • FAQ: What does YUTREPIA do that other treprostinil products do not?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Can the company fund the R&D increase it has announced without depleting cash?: Cash, investments and debt; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Cash runway cross-check (ours)
  • FAQ: Why are insiders selling if the business is performing this well?: Insider transactions, last 180 days; Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • FAQ: What is the breakeven point for cash generation, and when might the company reach it permanently?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.